Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Siemens Healthcare's Versant 440 molecular system

This article was originally published in Clinica

Executive Summary

Siemens Healthcare's Versant 440 molecular system has been awarded a supplementary PMA by the US FDA and may now be used in conjunction with the Versant HCV RNA 3.0 assay. The HCV RNA assay is used to manage the antiviral therapy given to hepatitis-C virus (HCV)-infected patients - interferon alfa-2b plus ribavirin. It measures HCV RNA levels at baseline and during treatment, and predicts the patients' virological response. The Versant 440 is a branched DNA system that bypasses nucleic acid extraction and reduces the risk of cross-contamination. It can integrate bar code data entry, automate reagent processing, perform signal amplification detection, and incorporates a Laboratory Information System which allows operators to download results. When run on the Versant 440, the HCV RNA 3.0 assay demonstrates "excellent precision across the entire reporting range and equivalent detection of all HCV RNA genotypes", Siemens claims. The Deerfield, Illinois firm CE marked the Versant 440 in September 2006, and has launched it throughout Europe, Africa, and parts of Asia and the Americas.

You may also be interested in...

ASH 2020: J&J/Legend’s Cilta-Cel Shines, But BMS/Bluebird’s Ide-Cel Is In First Place

Cilta-cel maintained high response rates in longer-term multiple myeloma data, but ide-cel causes less cytokine release syndrome and severe neurotoxicity – and it has a March decision date at the US FDA.

The Race To Develop A COVID-19 Vaccine: mRNA Pioneers Lead The Way

Our updated graphic tracker of key developments from the leading vaccine candidates.

LOXO-305 Comes Out Swinging In Battle Of BTK Inhibitors

Pathway open for drug as post-covalent BTK option as Loxo gears up for "risky" Phase III head-to-head study in Q1 2021.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts